Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Septerna, Inc. (SEPN : NSDQ)

• Company Description    Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 75

• Price / Volume Information    Yesterday's Closing Price: $25.44 Daily Weekly Monthly 20 Day Moving Average: 388,462 shares Shares Outstanding: 44.77 (millions) Market Capitalization: $1,139.05 (millions) Beta: 3.80 52 Week High: $29.74 52 Week Low: $4.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 32.22% 30.48% 12 Week 59.60% 55.03% Year To Date 11.09% -2.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 250 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-338-3533 fax: - investors@septerna.com https://septerna.com

• General Corporate Information    Officers Jeffrey Finer - Chief Executive Officer; President and Director Jeffrey Tong - Chairman and Director Gil M. Labrucherie - Chief Financial Officer Abraham Bassan - Director Bernard Coulie - Director Peer Information Septerna, Inc. (CORR.) Septerna, Inc. (RSPI) Septerna, Inc. (CGXP) Septerna, Inc. (BGEN) Septerna, Inc. (GTBP) Septerna, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81734D104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 44.77 Most Recent Split Date: (:1) Beta: 3.80 Market Capitalization: $1,139.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.92 Price/Cash Flow: - Price / Sales: 51.67 EPS Growth vs. Year Ago Period: 98.93% vs. Previous Quarter: 83.93% Sales Growth vs. Year Ago Period: 12,113.07% vs. Previous Quarter: 17,963.03% ROE 09/30/25 - -17.98 06/30/25 - -31.52 03/31/25 - -43.17 ROA 09/30/25 - -14.91 06/30/25 - -23.65 03/31/25 - -29.72 Current Ratio 09/30/25 - 6.53 06/30/25 - 22.09 03/31/25 - 32.19 Quick Ratio 09/30/25 - 6.53 06/30/25 - 22.09 03/31/25 - 32.19 Operating Margin 09/30/25 - -323.47 06/30/25 - -12,053.03 03/31/25 - -8,097.03 Net Margin 09/30/25 - -266.77 06/30/25 - -12,053.03 03/31/25 - -8,097.03 Pre-Tax Margin 09/30/25 - -267.49 06/30/25 - -12,093.80 03/31/25 - -8,138.48 Book Value 09/30/25 - 8.72 06/30/25 - 8.47 03/31/25 - 8.99 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©